; and (2) in paragraph (16), by adding at the end the following new subparagraph: (G) Access to non-opioid treatments for pain (i) In general Notwithstanding any other provision of this subsection, with respect to a covered OPD service (or group of services) furnished on or after January 1, 2020, and before January 1, 2025, the Secretary shall not package, and shall make a separate payment as specified in clause (ii) for, a non-opioid treatment (as defined in clause (iii)) furnished as part of such service (or group of services). (ii) Amount of payment The amount of the payment specified in this clause is, with respect to a non-opioid treatment that is— (I) a drug or biological product, the amount of payment for such drug or biological determined under section 1847A; or (II) a medical device, the amount of the hospital’s charges for the device, adjusted to cost. (iii) Definition of non-opioid treatment A non-opioid treatment means— (I) a drug or biological product that is indicated to produce analgesia without acting upon the body’s opioid receptors; or (II) an implantable, reusable, or disposable medical device cleared or approved by the Administrator for Food and Drugs for the intended use of managing or treating pain; that has demonstrated the ability to replace or reduce opioid consumption in a clinical trial or through clinical data published in a peer-reviewed journal, as determined by the Secretary. . (b) Ambulatory surgical center payment system Section 1833(i)(2)(D) of the Social Security Act ( 42 U.S.C. 1395l(i)(2)(D) ) is amended— (1) by aligning the margins of clause (v) with the margins of clause (iv); (2) by redesignating clause (vi) as clause (vii)